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Soy and red clover contain isoflavones. These bioactive plant substances are also called 
phyto-estrogens because their chemical structure is similar to that of the human hormone, 
estrogen. They can, therefore, also have a hormone-like effect. There are reports that Asian 
women who follow a traditional diet and regularly consume soy products scarcely suffer at all 
from menopausal complaints. However, opinions differ as to whether this can be attributed to 
a diet that is rich in soy. Furthermore, when looking at the assumed effects of isoflavones, a 
distinction must be made between whether they are ingested naturally from food or in iso-
lated, fortified form via food supplements. In Germany for some time now food supplements 
with isolated isoflavones have been available on the market as an alternative to the pre-
scribed hormone replacement therapy for menopausal complaints. The products are claimed 
to be efficacious natural products without any side effects. Against this backdrop, the Federal 
Institute for Risk Assessment (BfR) has undertaken a health assessment of isoflavone-
containing food supplements.  
 
To this end BfR evaluated a number of scientific studies. It revealed that, according to the 
latest scientific knowledge available, the assumed positive effects of isolated isoflavones on 
menopausal complaints have not been sufficiently substantiated. The adverse effects re-
ported to BfR like nausea, constipation, swelling or reddening are possibly caused by allergic 
reactions to the soy protein contained in these products or to other factors. BfR is of the opin-
ion that the toxicological risks regarding the hormonal situation of female users are to be 
viewed more critically than these short-term, acute adverse effects. 
 
Toxicological studies showed that isoflavones, when administered at high doses in isolated 
or fortified form, impair the functioning of the thyroid gland and can change mammary gland 
tissue. It cannot be ruled out that these estrogen-like effects could promote the development 
of breast cancer. The necessary long-term studies, to prove the safety of isoflavone-
containing products, are not available. Nor is it possible, at the present time, to reliably estab-
lish a dose which could be considered safe. As women during and after menopause are at 
increased risk of breast cancer, the long-term intake of food supplements with a high level of 
isoflavones is not without risk for this consumer group. 
 
1 Subject matter of the assessment 
 
The Federal Office for Consumer Protection and Food Safety (BVL) has received repeated 
reports of the adverse effects of soy and red clover-containing products. These products had 
been placed on the market as foods/food supplements and were recommended above all for 
post-menopausal women. However, not all the products had been notified pursuant to § 5 
Food Supplements Ordinance (NemV) to BVL.  
 
As there have been several incidences of adverse effects of soy and red clover-containing 
products, the Federal Institute for Risk Assessment (BfR) has undertaken a health assess-
ment of them. 
 
2 Results 
 
The reports about the adverse effects of soy/red clover-containing products do not refer to 
uniform sets of symptoms and point to allergic reactions and/or other causes, perhaps to the 
basic symptoms of the menopausal complaints of the persons concerned. The adverse ef-
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fects are linked to various food supplements including ones which contain or contained other 
possible causal substances besides isoflavones, like nicotinic acid - a source of niacin. The 
daily intake of isolated isoflavones from soybeans was 40, 50 or 80 mg. In one case the daily 
intake included an additional 250 mg red clover extract. 
 
At the present time, the claimed favourable effects of isolated isoflavones on menopausal 
complaints as well as other advantageous health effects on the heart, bones and breasts 
must be deemed to be not sufficiently scientifically substantiated. The potential of isolated 
isoflavones to trigger adverse health effects (e.g. on the human mammary gland, uterus, 
thyroid gland) and the dose-dependency of side effects of this kind have not been sufficiently 
investigated up to now. Post-menopausal women are the main risk group for these adverse 
effects arising from the consumption of isoflavone-containing products made from soy and 
red clover. For the time being, BfR therefore advises against the long-term intake of these 
products given the unproven positive effects and the serious health consequences for meno-
pausal women which cannot be ruled out. Bearing in mind the special health sensitivity of 
this consumer group, BfR comes to the conclusion that the safety of products containing iso-
lated isoflavones on a soy or red clover basis, which are placed on the market as food sup-
plements or foods for special medical purposes, has not been sufficiently proven. In addition, 
BfR concludes that there are health risks with low probability from food supplements of this 
kind for women during and after menopause. 
 
3 Reasons 
 
3.1 Risk assessment 
 
Risk assessment encompasses both the notified adverse effects of soy/red clover-containing 
products, the biological effects of the isoflavones contained in them, and their toxicity with 
regard to the food safety requirements applicable to food supplements. 
 
3.1.1 Ingredients 
 
Isoflavones are the main ingredients of soy or red clover-containing products. They belong to 
the family of phyto-estrogens which, in their capacity as bioactive plant substances, have a 
similar receptor-relevant subspace to estradiol. This means that they bind to various estro-
gen receptors and may trigger estrogen action on the human organism. 
 
Isoflavones made from soybeans (Glycine hispida max) are mixtures mainly of daidzein, gen-
istein and glycitein or their glycosides daidzin, genistin and glycitin (= binding to sugar mole-
cule). Soybeans deliver the isoflavones genistein, daidzein and glycitein roughly on a ratio of 
10:8:1 (Wolters/Hahn, 2004). Whole soybeans and non-fermented soy foods mainly contain 
isoflavones as sugar conjugates in the glycoside form. The glycosylated isoflavones are less 
active than the free isoflavones (aglucones). Depending on processing the ratio of free to 
glycosylated may vary. For instance, fermented soy foods (e.g. tempeh) have a higher share 
of isoflavone aglucones than non-fermented ones like, for instance, tofu (Wang and Murphy, 
1994).  
 
Red clover (Trifolium pratense) contains many compounds with an isoflavone structure. The 
main components are formononetin and biochanin A, which is the 4'-methyl ether of daidzein 
and genistein. Furthermore genistein, daidzein and glycitein as well as the isoflavones irilon, 
prunetin, pratensein, pseudobaptigenin, calycosin and orobol can also be detected in red 
clover (Wu et al., 2003).  
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Isoflavone-containing red clover or soy extracts are not nutrients. It should, therefore, be ex-
amined whether isoflavones can be deemed to be other substances with a specific nutritional 
or other physiological effect subject to the precondition that they can be classified as safe for 
consumption as foods. 
 
3.1.2 Hazard potential (observed adverse effects) 
The hazard potential of isoflavones and their main metabolites is linked to the fact that they 
can interfere with the hormonal balance which, depending on the dose, can have positive but 
also adverse effects (Osoki and Kennelly, 2003; Setchell and Cassidy, 1999). Besides the 
short-term, observed adverse effects, BfR also examined the possible long-term carcino-
genic and goitrogenic effects on the thyroid gland. The effects of intakes which are to be ex-
pected from food supplements or foods for special medical purposes, must be examined on 
a case-by-case basis (SKLM, 2005). 
 
Pharmacies reported various products in connection with the observed adverse effects. 
Isoflavones made from soy or red clover extracts were listed as ingredients on the packag-
ing. The attached reports on side effects from 2003-2005 indicate that the listed adverse ef-
fects disappeared in all female patients once they stopped taking them and that none of 
these products had been prescribed by a doctor. 
 
BfR had already received reports of various adverse effects to soy-containing/red clover-
containing products which were placed on the market as foods in the Federal Republic of 
Germany. Between 2002 and 15 September 2006 a total of 21 reports were received. These 
were "spontaneous reports" for most of which there were no medical examinations or find-
ings. Some of these reports will probably correlate with the cases of adverse effects men-
tioned by BVL. 
 
Aside from one case involving soy milk, all the other products consumed are described as 
food supplements containing isolated fortified isoflavones in which the original food structure 
is no longer present. The reported adverse effects of soy-containing/red clover-containing 
products occurred under normal use, involve non-uniform pictures of the complaints and 
point to allergic reactions, flushing syndrome and/or other causes. They may also point to the 
basic symptoms of the menopausal complaints which have to be treated. 
 
The adverse effects are mainly described as minor and, in some cases, as moderate. They 
are: rhinitis, skin tension, swelling not described in more detail, allergies, local oedema, red-
dening skin/mucosa; itching, flushing, exanthema, swelling skin/mucosa, eczema, myalgia, 
nausea, dizziness, urticaria, high systolic and diastolic blood pressure, respiratory distress, 
tingling, abdominal pain, pain not described in more detail, skin rash, tachycardia, circulatory 
complaints, dizziness, tachypnoae, fertility disorders, exhaustion, coughing, sputum, agita-
tion, indisposition, sweating, anxiety, thorax pain, paraesthesia, precordial pain. 
 
3.1.3 Exposure (sources, incidences) 
 
Soybeans contain approximately 1-3 mg isoflavones per gram raw material, i.e. approxi-
mately 0.1-0.3%. Traditional soy-containing foods supply approximately 30 mg isoflavones 
per portion. The weight of sugar in the glycoside is almost as high as that of the isoflavone 
itself (around 40% of the total weight of the glycoside). Hence, the actual isoflavone content 
is correspondingly lower than the content of the isoflavone glycoside. Soybeans have isofla-
vone levels of 0.2-1.4 mg/g dry weight (Head et al., 1996).  
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In Asian countries fermented soy products like tempeh, miso or natto are part of a traditional 
diet. This leads to a daily isoflavone intake of around 15-50 mg, mainly as aglucones (Munro 
et al., 2003; Setchell et al., 2001; Messina, 1995). By contrast, in western industrial countries 
soy products are not conventional foods which means that on average there is a daily intake 
of less than 2 mg isoflavones (Cassidy, 2005; Kroll et al., 2004; Munro et al., 2003). 
 
The daily intake of isolated isoflavones from soybeans via food supplements was 40, 50 and 
80 mg; in one case the daily intake included an additional 250 mg red clover extract. 
 
3.1.4 Bioavailability, metabolism and excretion 
 
After oral intake free isoflavones (aglucones) appear to be absorbed more quickly than the 
glycosylated forms which must first be cleaved in the lower small intestine by beta glucosid-
ses. The bioavailability of free isoflavones seems, however, to be slightly lower than of gly-
cosylated isoflavones (Setchell et al., 2001). Scientific opinions in the literature disagree 
about the extent to which the bioavailability of glycoside and aglucone differ and this is the 
subject matter of further studies (Kroll et al., 2004). The level of absorption is said to be 
around 20-55% (Wolters and Hahn, 2004). Examination of the bioavailability of isoflavones in 
isolated form as capsules and intake as a soy drink made of soy flour and water revealed 
comparable results for genistein from both isoflavone sources whereas daidzein had signifi-
cantly lower bioavailability from the soy drink than from the isolated capsule form (Anupong-
sanugool et al., 2005). In the liver the isoflavones are coupled to glucuronic acid or sulphate. 
Excretion is mainly renal, a lower proportion via the biliary route. Similar to endogenous es-
trogens, the enterohepatic circulation of isoflavones excreted in bile is possible. Although this 
may vary considerably from individual to individual and depending on the colon flora, further 
metabolisation of non-resorbed isoflavones may take place in the small intestine. For in-
stance daidzein may be metabolised into O-desmethylangolensin or equol or genistein into 
6'-hydroxy-O-desmethylangolensin and into other metabolites (Joannou et al., 1995; Winter, 
1989; Wolters and Hahn, 2004). Furthermore, isoflavones are also substrates for cyto-
chrome-P450-dependent monooxygenases which are mainly localised in the liver. Hence 
genistein and daidzein are metabolised in vitro into a large number of hydroxylated deriva-
tives which in some cases could also be detected in urine following soy consumption (Kulling 
and Watzl, 2003). 
 
The bioavailability of isoflavones, measured as percentage excretion in faeces and urine, 
varies from individual to individual and is dependant on various variables like gender, proc-
essing of the food, food matrix, intestinal flora, passage time and type and amount of dietary 
fibre ingested (Adlercreutz, 1990; Morton et al., 1994; Tew et al., 1996; Xu et al., 1995; 
Przyrembel, 1998; Rowland et al., 2003; Munro et al., 2003). Equol has a relatively higher 
estrogen potency than its precursor daidzein. However, not everyone is capable of producing 
equol and quantitative data on the rate of the equol producers differ (Setchell et al., 2001). 
More recent studies indicate that around 30% of adults are capable of the intestinal conver-
sion of daidzein into equol (Morton et al. 1994; Cassidy et al., 2006). 
 
In the case of Asians on a traditional diet, i.e. regular consumption of soy-containing foods, 
concentrations of total isoflavonoids (sum of daidzein, genistein and equol) were measured 
in the plasma of 870 nmol/l (nanomol per litre) whereas in Europeans because of the lower 
intakes of isoflavones (< 2 mg/day) on average only approximately 10 nmol/l were found 
(Adlercreutz et al., 1993). Morton et al. compared the serum values of a total of 400 people 
over the age of 40 from Japan and the United Kingdom. The mean values for daidzein and 
genistein in Japanese men were 282.5 nmol/l and 492.7 nmol/l respectively. Japanese 
women had very similar values of 246.8 nmol/l and 501.9 nmol/l. In comparison the mean 
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values for daidzein and genistein in people from the United Kingdom were 17.9 nmol/l and 
33.2 nmol/l for men and 12.5 nmol/l and 27.7 nmol/l for women (Morton et al., 2002).  
 
3.1.5 Biological effects and toxicity 
 
Isoflavones can trigger various biological effects which are said to contribute to the health 
advantages of soy-containing foods (Knight and Eden, 1996). The various metabolites of 
genistein and daidzein differ considerably from one another both in terms of their efficacy 
and their mechanism of action. Even small differences in chemical structure, for instance an 
additional hydroxyl or methoxy group or the lack of a covalent bond, can have a major impact 
on the biological activity of the compounds. The list of biological effects of isoflavones is long 
and encompasses hormonal and non-hormonal effects. The most well examined is the effect 
of phyto-estrogens induced by the estrogen receptors. In the body the two ERα and ERβ are 
distributed differently. In some cases, the data in the scientific literature vary regarding the 
distrubution of the sub-types of the estrogen receptor system in the individual tissues. There 
are reports of the receptor binding affinity of isoflavones to both ERα, and ERβ although,a 
higher binding affinity to ERβ is assumed (Kulling and Watzl, 2003; NAMS, 2000; NAMS, 
2004; Gruber et al., 2002; Allred et al., 2004; Harris, 2005). 
 
Regarding the use of isoflavones in food supplements and foods for special medical purpo-
ses and the target group of women with menopausal complaints, in the present paper only 
the biological effects because of their estrogen impact on menopausal complaints should, 
however, be examined as an alternative to hormone replacement therapy along with the po-
tential anti-carcinogenic and pro-carcinogenic effects of isoflavones on the female mammary 
glands, uterus and possible adverse effects on the thyroid gland. 
 
3.1.5.1 Effects on women during menopause 
 
Because of their assumed estrogen-agonistic or estrogen-antagonistic effects, phyto-
estrogens are said to have numerous tissue-specific effects, probably dependent on the indi-
vidual amount of endogenous estrogens and the number and type of estrogen receptors.  
Their affinity to the estrogen receptor is estimated to be between 1,000 and 10,000 times 
lower than that of estradiol (Przyrembel, 1998; Wolters and Hahn, 2004). Through interaction 
with the estrogen receptors, isoflavones can imitate or block the physiological effect of the 
endogenous steroid hormone. Compared with 17ß-estradiol (natural estrogen), their estro-
genic effect is – on the one hand - at least 100 times lower. On the other hand, isoflavones in 
the body may be present in a concentration which is between 100 and 10,000 times higher 
than the endogenous estrogens. Depending on the level of the endogenous estradiol, phyto-
estrogens may have an estrogenic as well as an anti-estrogenic effect. Compared to soy the 
red clover extract demonstrated a 50 times higher affinity to the estrogen receptor (Beck et 
al., 2003). 
 
Because of the discussions about hormone replacement therapy in menopausal women and 
the possible side effects of estrogens, interest in alternative treatment methods has grown. 
This includes isoflavone-containing products which are placed on the market as food sup-
plements or foods for specific medical purposes. On the product packaging, in the enclosed 
product information or corresponding advertising, isoflavones and, by extension, the corre-
sponding products are frequently described as efficacious, side effect-free natural sub-
stances or natural substance products for menopausal complaints or are described as having 
advantageous health effects for heart, bones and breasts although the claimed effects have 
not been sufficiently proven. BfR has, therefore, assessed a series of current overviews and 
meta-analyses from the efficacy angle. 
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According to a review by Cassidy, 2005, no adverse effects were documented in various, 
published, clinical trials lasting between one and six months with an intake of between 3 mg 
and 131 mg isoflavones per day (as aglucone equivalents). However, this study does make 
reference to substantiated assumptions that isoflavones could have potentially genotoxic and 
carcinogenic effects and that extrapolations to the human situation only permitted unreliable 
interpretations. No clear proof was provided of the clinical efficacy of isolated soy isoflavones 
in conjunction with hot flushes as symptoms of menopause. The question about the possible 
effects of isoflavones on various organs or organ systems was examined. The author came 
to the conclusion, "There is a great need for long-term prospective studies and clinical trials 
to derive empirical proof of the efficacy and safety of isoflavones and to fully explore their 
potential role in preventative medicine" (Cassidy, 2005). 
 
In a review by Krebs et al., 2004, 25 published comparative clinical trials from between 1966 
and 2004 were examined with a total of 2,348 participants with menopausal complaints. In 
studies in which soy-rich foods were examined, the total daily intake of isoflavones was an 
estimated 34-134 mg. No favourable effect was observed compared to the control group. In 
studies in which isolated soy isoflavones from various manufacturers were examined in cap-
sule or tablet form against placebo, the daily dose was indicated as 50-150 mg isoflavones. 
The results were not consistent. In studies in which isoflavones isolated from red clover were 
examined,  there were no statistically significant more favourable effects on the menopausal 
symptoms compared with the placebo overall. The reported side effects included gastrointes-
tinal complaints, unpleasant taste of the supplements and in one study vaginal spotting. The 
authors came to the conclusion: "The available evidence suggests that phytoestrogens avail-
able as soy foods, soy extracts, and red clover extracts do not improve hot flushes or other 
menopausal symptoms" (Krebs et al., 2004). The authors pick out the study by Tice et al., 
2003 as being of relatively good quality. Tice and his staff examined isoflavones isolated 
from red clover in a double blind, placebo-controlled 12-week study involving 252 women 
with menopausal complaints. Comparable effects were observed in the three groups exam-
ined: "Promensil", 82 mg total isoflavones per day, "Rimostil", 57 mg total isoflavones per day 
and placebo (reduction in hot flushes of between 34% and 41% in the course of the 12 
weeks). The authors concluded, "Although the study provides some evidence for a biological 
effect of Promensil, neither supplement had a clinically significant effect on hot flashes or 
other menopausal symptoms when compared with placebo" (Tice et al., 2003). 
 
In another review from 2003/2004 the authors came to the conclusion that there are some 
signs of favourable effects of soy isoflavones on vasomotor symptoms in conjunction with the 
menopause but that because of the heterogeneity of the observed studies no clear statement 
is possible, "There is some evidence for the efficacy of soy preparations for perimenopausal 
symptoms. However, the heterogeneity of the studies performed to date means it is difficult 
to make a definitive statement". Ten randomised, controlled clinical studies from 1995-2002 
with soy or isolated soy isoflavones as monotherapy were analysed, not as part of a diet rich 
in phyto-estrogens. The target criterion was vasomotor symptoms like "hot flushes" or "peri-
menopausal symptoms". A daily dose of between 34 mg and 134 mg isoflavones was admin-
istered. The studies lasted between six and 24 weeks. The main side effects observed were 
gastrointestinal complaints like nausea, constipation, unpleasant taste, bloatedness as well 
as allergic reactions to soy. The authors stress that isoflavones do not appear to have any 
serious side effects in conjunction with short-term use but that risks in conjunction with long-
term administration have not yet been examined (Huntley and Ernst, 2004). 
 
The North American Menopause Society (NAMS) concludes in its position paper that the 
current data situation on soy isoflavones is not sufficient either to advocate their use to treat 
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mild vasomotor symptoms ("mild hot flashes") or to refute them ("... clinical trial results are 
insufficient to either support or refute efficacy for soy foods and isoflavone supplements (from 
either soy or red clover), ... however, no serious side effects have been associated with 
short-term use of these therapies" (NAMS, 2004). In the 14 controlled clinical trials involving 
women with vasomotor symptoms in conjunction with the menopause assessed by NAMS, 
preparations with daily doses of 40-80 mg isoflavones were mainly used. It is stressed that 
nothing is known about the long-term effects of isolated isoflavones or foods fortified with 
isoflavones. Nor are there any findings about whether it is safe for women with a (known) 
mammary carcinoma to use them or whether there is a risk. 
 
The American Heart Association Nutrition Committee comes to the conclusion in its current 
assessment from 2006 that soy isoflavones were not able to convincingly demonstrate a sig-
nificantly favourable effect on vasomotor symptoms in conjunction with menopause. In the 
more than 20 clinical trials assessed, the recognisable improvements in symptoms both in 
the placebo and control groups as well as in the isoflavone groups over time were frequently 
between 40% and 60%. Because of the unclarified risks and inadequate data, the Associa-
tion advises against the consumption of food supplements with isolated isoflavones and 
foods fortified with isoflavones. The Association stresses that conventional soy-containing 
foods can generally have a favourable impact on health because they often contain higher 
amounts of polyunsaturated fatty acids, dietary fibre, vitamins and minerals as well as a 
lower proportion of saturated fatty acids (Sacks et al., 2006). 
 
Nelson et al., published a review combined with a meta-analysis of placebo-controlled clinical 
trials with isoflavones made from red clover extracts (six studies from 1999-2004; daily dose 
40-80 mg isoflavones; duration between 12 weeks and 12 months; approximately 600 
women with vasomotor complaints like "hot flushes"; all six trials were included in the meta-
analysis) and isoflavones from soy extracts (11 trials from 2000-2005, six from 2000-2004 
were included in the meta-analysis; daily dose 54-600 mg; duration between four weeks and 
one year; approximately 600 women with vasomotor symptoms like hot flushes). The authors 
described the results as follows, "The trials do not support the efficacy of red clover isofla-
vone extracts and present mixed results for soy isoflavone extracts. ... Hot flash frequency 
was not reduced when all trials of red clover isoflavone extracts were combined, and results 
for soy isoflavone extracts were contradictory even among the largest and highest quality 
trials. These results are consistent with other recent systematic reviews. We also reviewed 
trials of other forms of soy isoflavones, such as flour, powder, and food items, in another 
study. However, these trials are difficult to compare because of variability of components and 
doses. Overall, evidence does not support benefit in relieving hot flashes" (Nelson et al., 
2006; Tice and Grady, 2006). 
 
The therapy recommendations of the Medicinal Products Committee of German Doctors 
(Arzneimittelkommission der Deutschen Ärzteschaft) "Hormonal therapy during menopause" 
2003, adopts a position on the use of isoflavone extracts, including red clover extracts, soy 
and soy extracts and comes to the conclusion that preparations of this kind should not be 
seen as an alternative to estrogen therapy "not just because of the inconsistent study situa-
tion but also until sufficient data become available on the long-term efficacy and safety of 
these products some of which are also commercially available in Germany" (AVP, 2003). 
 
3.1.5.2 Adverse effects and toxicity 
 
3.1.5.2.1 Carcinogenic effects 
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Global cancer statistics indicate that hormone-dependent cancer diseases like cancer of the 
breast and prostate occur far less frequently amongst the Asian population for whom soy is 
of greater importance in their diet than in western countries (Pisani et al., 1999). For that rea-
sons various studies examined the effects of soy protein and isoflavones on the development 
of breast cancer in fully grown adult animals. The data obtained are not completely un-
equivocal but do generally show that the addition of soy or isoflavones to a standard diet 
does not markedly reduce the tumour incidence as a rule but does reduce in most cases the 
amount of tumours (the number of tumours in individual animals) by between 25-50% (Hak-
kak et al., 2000; Zaizen et al., 2000; Gotoh et al., 1998; Barnes et al., 1990). By contrast, the 
18 epidemiological studies (12 case studies and six prospective cohort studies) conducted in 
Asia did not always back the assumption that the consumption of soy by adult Asian women 
reduces the risk of breast cancer after menopause. The results of the meta-analysis must be 
interpreted cautiously as the exposure data were referred to "gram soy protein", there is no 
dose-dependency and the reduction in the breast cancer risk observed in a few studies can-
not be attributed to soy intake as the sole factor but to so-called confounders when evaluat-
ing this data (Martinez  et al., 2006; Trock et al., 2000; 2006).   
 
According to more recent findings the improved iodine supply of the Asian population com-
pared with the female population in Europe is seen as one such confounder which may ex-
plain the lower incidence of breast cancer amongst Asian women. Asian and, above all, 
Japanese women have a daily intake of around 1 mg iodine mainly from their higher con-
sumption of marine fish and iodine-rich seaweed consumption (Venturi, 2001). Women who 
develop nodular goitre as a consequence of chronic iodine deficiency have a higher inci-
dence of breast cancer (Turken et al., 2003). Iodine lactones, which inhibit the growth of thy-
roid cells, are also formed in mammary gland cells and thereby inhibit their proliferation or 
induce apoptosis. When given an iodine-deficient diet young rats develop ductal hyperplasia 
and perilobular fibrosis of the mammary gland (mastopathy) which can be prevented by suffi-
cient iodine intake (Eskin et al., 1995). Animal experiments showed that 5% seaweed in feed 
can significantly delay the onset of chemically induced mammary carcinoma (Funahashi et 
al., 1999; 2001). The administration of iodine to women with a mastopathy significantly re-
lieved the symptoms (Ghent et al., 1993). Improved iodine supply leads to a higher synthesis 
of iodine lactones in the mammary gland cells which not only reduces the incidence of be-
nign mastopathy but also of breast cancer (Smyth, 2003; Venturi, 2001).  
  
Animal data on the chemopreventive effect of soy isoflavones on breast cancer do not pro-
duce a clear picture. In animal experiments (female rats) the occurrence and the growth rate 
of chemically induced tumours could be considerably reduced when soy or the isolated soy 
isoflavone genistein was administered prior to the onset of puberty. However, if this sub-
stance was not administered until adult age, there was no longer any protective effect (La-
martiniere et al., 2002). This could be one possible explanation for the fact that in the epide-
miological studies which assessed soy consumption in adults, no effect was observed on the 
growth of breast cancer. 
 
In other animal experiments (mice with implanted human breast cancer cells) the administra-
tion of genistein or a soy protein isolate provoked an accelerated growth of these tumour 
cells. This experiment was confirmed by studies in cell cultures (Ju et al., 2001; 2006). The 
plasma concentrations reached in these animal experiments with isoflavones of 1-2 μmol/l 
were in a concentration range which could indeed be achieved through taking food supple-
ments. The effect was recently confirmed by another working group (Power et al., 2006; 
Saarinen et al., 2006). 
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The exposure of rats during pregnancy led in their offspring to a dose-dependent increase in 
the post-natal induced breast cancer rate (Hilakivi-Clarke et al., 1999) caused by the car-
cinogen DMBA (7,12-dimethyl-benz(a)anthracene). Furthermore, the administration of gen-
istein or a genistein-rich soy extract promoted the induction of precursor tumour stages in the 
intestines of rats by the carcinogen 1,2-dimethyl hydrazine (Gee et al., 2000). 
 
Other animal experiments and in-vitro studies showed that low concentrations of isoflavones, 
like the ones measured in human plasma after consumption of soy products, stimulate the 
growth of tumour cells whereas the desired growth inhibition was only achieved at high con-
centrations (Dampier et al., 2001; Hsieh et al., 1998; Hsu et al., 1999). In healthy women with 
a reduced secretion of hormones from the ovaries, plasma concentrations of 3 and 11 µmol/l 
of genistein and daidzein respectively were measured after consuming a soy-containing diet 
(Lu et al., 2000). In other healthy volunteers, too, only plasma concentrations < 4 µmol/l were 
measured after taking large single doses of these two compounds (0.6-0.9 mg/kg body 
weight) (King and Bursill, 1998). These concentrations can be compared rather with the low 
plasma concentrations at which in vivo stimulation of tumour growth was observed (Zava and 
Duwe, 1997) than with the high concentrations in vitro associated with inhibition of tumour 
growth (Nakagawa et al., 2000; Santell et al., 2000; Dees et al., 1997; Sathyamoorthy et al., 
1997; Wang and Kurzer, 1997; Sathyamoorthy and Wang, 1994). 
 
In the literature there are isolated studies on the interaction between isoflavones and ta-
moxifen. In one animal experiment with ovariectomised athymic mice, into which MCF-7 cells 
were implanted, tamoxifen inhibited the estradiol-induced proliferation of tumour cells. This 
effect was negated by the parallel administration of feed fortified with genistein (Ju et al., 
2002). In a further study with transgenic mice (wild type erbB-2/new) treatment with ta-
moxifen prevented the development of tumours. This effect was also negated by a low dose 
of isoflavone fortified feed (Liu et al., 2005). 
 
Discussions about the safety assessment of isoflavones look at whether the time of phyto-
estrogen exposure in specific development stages of man, for instance in childhood or in 
puberty, could be a decisive factor when it comes to the question of favourable or adverse 
effects. The question about any pro-carcinogenic effects of isoflavones cannot be answered 
definitively at the present time either (Wolters and Hahn, 2004; Sacks et al., 2006; Wuttke et 
al., 2002). The Medicinal Products Committee of German Doctors refers in this context to the 
possible stimulating effects of phyto-estrogenic soy components on the cell proliferation of 
normal breast tissue and mammary tumours (AVP, 2003; Petrakis et al., 1996, McMichael-
Phillips et al., 1998, De Lemos, 2001; Hargreaves et al., 1999; Wuttke et al., 2002). Other 
authors also refer to toxicological studies that provided some indication of a possible unfa-
vourable impact of isoflavones on the proliferation of mammary gland tissue and endo-
metrium (Kroll et al., 2004). 
 
Several studies have examined the effects of soy consumption on cell proliferation or of bio-
markers on the cell proliferation of mammary gland tissue in women. Hargreaves et al., 
(1999) examined the effect of the 14-day administration of 60 g soy (48 mg total isoflavones) 
per day on the mammary gland tissue of premenopausal women. Whereas no effects could 
be observed on the estrogen receptor status, proliferation, apoptosis (programmed cell 
death) or mitosis of the epithelial mammary gland cells, the concentrations of apolipoprotein 
D fell significantly and the expression of the gene pS2, which responds significantly to estro-
gen, increased. This is a sign of a weak estrogen effect. In another randomised clinical trial 
women (n=48) with benign and malignant breast diseases were given a soy protein-
containing food supplement (45 mg isoflavones) daily for a period of 14 days. In biopsy mate-
rial with the help of the labelled [3H]-thymidine and immunohistochemically labelled prolifera-
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tion antigen Ki67, the impact was examined on the proliferation rate of premenopausal, his-
tologically normal mammary gland epithelium and the expression of the progesterone recep-
tor. Soy supplementation led to a significant increase in both the proliferation rate and ex-
pression of the progesterone receptor after 14 days. In the opinion of the authors further 
long-term studies are needed in order to be able to rule out any adverse health effects 
(McMichael-Phillips et al., 1998). 
 
On the other hand in one study with 23-42 year old women with a regular cycle (n = 10) who 
were given daily approximately 1 litre soy milk from homogenised whole soybeans with on 
average 154 mg total isoflavones daily over a period of one month, a drop was observed of 
25% in the values circulating in the blood for 17-beta-estradiol and a drop of 45% in the val-
ues for progesterone compared with the values measured in conjunction with a normal diet in 
previous cycles. The soy milk did not manifest any effect on the level of the values for the 
hormones LH and FSH. Furthermore, under the soy diet the mean cycle length was also un-
changed (Lu et al., 2000). The plasma values for daidzein and genistein were 2.89 µg/ml and 
0.85 µg/ml respectively equivalent to 11.3 µmol/l and 3.1 µmol/l respectively. From the study 
the authors concluded that various components of a soy diet – including isoflavones – are 
capable of directly modulating ovarial hormones without influencing gonadotropins and de-
duced from this implications for the prevention of breast cancer. 
 
148 women, who were given soy for a period of three to four months during infancy, reported 
significantly longer menstruation, more severe menstruation complaints and more frequent 
use of anti-asthmatic and anti-allergic medicines (Strom et. al., 2001). Because the impor-
tance of these findings is unclear and because infants fed on soy can reach very high plasma 
levels of isoflavones (1-4 µmol/l) (Setchell et al., 1998) whose long-term effects cannot be 
estimated, European, German and Swiss associations for paediatrics and youth medicine 
recently recommended that soy infant formula should only be used in the case of special 
indications (Agostoni et al., 2006; Böhles et al., 2006). 
 
In a long-term study the influence of isolated phyto-oestrogens was examined on the endo-
metrium (Unfer et al., 2004). The randomised, double blind, placebo-controlled clinical trial in 
women during and after menopause observed histologically stimulating effects of isolated 
soy isoflavones on the endometrium. The verum group (n=179) was given three tablets daily 
with 50 mg soy isoflavones (150 mg daily dose containing 40-45% genistein, 40-45% 
daidzein and 10-20% glycitein) for five years whereas the control group (n=197) was given 
the placebo. Endometrial biopsies were conducted at the beginning of the trial, after 30 
months and after five years treatment. 298 women who had received treatment over five 
years reached the end of the trial. Whereas after 30 months in both groups no hyperplasias 
were observed in the endometrium, hyperplasias of this nature were observed after five 
years in six women (3.4%) in the verum group but not in the placebo group. This difference 
between the treatment groups was statistically significant. Carcinomas were not observed. 
The study provides some indication of adverse estrogen-like effects on the endometrium in 
humans following the long-term intake of isolated soy isoflavones. As a consequence the 
authors of this study have questioned the safety of isoflavones when administered for long 
periods in conjunction with an increase in endometrium hyperplasias in women during and 
after menopause (Unfer et al., 2004). Experimental results in rats point in the same direction. 
Coumestrol, a phyto-oestrogen in the family of isoflavonoids, accelerated growth of the 
uterus mucosa induced by steroidal estrogen (Whitten et al., 1995). 
 
3.1.5.2.2 Allergenicity of soy 
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Depending on their manufacture, isolates from soybeans contain different amounts of soy 
protein which is one of the most well known food allergens. No quantitative data are, how-
ever, available. The incidence of a soy allergy is estimated to be 0.3-0.4% of the total popula-
tion. Foods, to which soy or soy products have been added, must be labelled pursuant to 
European food law (EFSA, 2004). A threshold dose for the triggering of symptoms in patients 
allergic to soy cannot be indicated although in the case of immediate IgE-mediated allergies, 
doses of less than one milligram allergen or 500 mg of soy-containing foods and beverages 
were sufficient (Binslev-Jensen et al., 2002; Sicherer et al., 2000). There is no information on 
doses for delayed non-IgE-mediated allergic reactions to soy with clinical symptoms, mostly 
in the gastrointestinal tract.  
 
Furthermore, it was observed that people with a birch pollen allergy may also have a cross-
allergy to soy protein. A specific stress protein from soybeans, which has since been given 
the name Gly m 4, has a sequence homology of more than 50% with the birch pollen aller-
gen Bet v 1. Hence patients with a birch pollen allergy can manifest immediate allergic reac-
tion after eating soy protein-containing foods (Kleine-Tebbe et al., 2002; Mittag et al., 2004; 
Süß et al., 2005). The patients concerned who consume soy may suffer symptoms similar to 
oral allergy syndrome (OAS) such as itching, papules, blisters around the mouth, swollen 
lips, glottic oedema, dysphagia and dyspnoea. The course of AOS may vary considerably: 
from mild which are only subjectively unpleasant over rare courses which spread to other 
organs down to cardiovascular symptoms which can lead, amongst other things, to anaphy-
lactic shock. 
 
3.1.5.2.3 Goitrogenic effects on the thyroid gland 
 
Genistein and daidzein can inhibit the activity of thyroid gland peroxidase, which is essential 
for the synthesis of thyroid hormones, at concentrations of 1-10 µmol/l in vitro. This inhibition 
is reversible in the presence of iodine (Divi et al., 1997). The half-maximal inhibition (IC50) of 
thyroidal peroxidase is already reached at a concentration of 1 μm genistein. It is not yet 
clear to what extent these data obtained from in vitro studies are of physiological relevance 
(Doerge and Sheehan, 2002).  
 
As observed by the DFG Senate Commission on the health assessment of foods (SKLM, 
2006), a second point of attack of isoflavones in thyroid hormone metabolisation is inhibition 
of the sulphotransferase enzymes involved in the inactivation and elimination of thyroid hor-
mones and local recovery of iodine in the human thyroid gland (Ebmeier and Anderson, 
2004). A third point of attack of isoflavones in the thyroid hormone axis is transthyretin (TTR, 
formerly thyroxin-binding prealbumin, TBPA). In serum TTR binds up to 20% of thyroxin (T4), 
is involved in the distribution of T4 in the body and in preventing T4 excretion in the kidneys. 
TTR is the most important thyroid hormone-binding protein in cerebral spinal fluid (CSF). In 
serum and CSF, genistein and related isoflavones are highly efficacious inhibitors of T4 and 
T3 binding to TTR (Kd = 40 nmol/l, equimolar to T4 binding). They alter the distribution of thy-
roid hormones in the body (Green et al., 2005; Radovic et al., 2006).  
 
3.1.6 Risk characterisation 
 
3.1.6.1  Adverse effects on hormone balance 
 
The potential hazards of isoflavone-containing products lie above all in their stimulating effect 
on the growth of breast cancer and the negation of the tumour-inhibiting effect of tamoxifen 
as an estrogen blocker during the treatment of estrogen-dependent tumours. This is backed 
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by findings from in vitro and animal studies that low concentrations of genistein and daidzein 
(< 10 µmol/l) promote tumour growth, whereas high concentrations of genistein (> 10 µmol/l) 
inhibit the growth of breast cancer and reinforce the tumour-inhibiting effect of tamoxifen (Ju 
et al., 2002; Dampier et al., 2001; Hsieh et al., 1998; De Lemos, 2001; Dees et al., 1997; 
Nakagawa et al., 1997; Wang and Kurzer, 1997; Zava and Duwe, 1997; Sathyamoorthy et 
al., 1997; Sathyamoorthy and Wang, 1994). The concentration-dependent biphase effect 
would seem to indicate that the safety of phyto-estrogens depends on the amount ingested. 
It is not, however, clear whether the concentrations used in vitro can be equated with the 
concentrations reached in vivo. Particularly in the case of women with an elevated risk of 
breast cancer or an existing mammary carcinoma, the pre-carcinogenic effects of phyto-
estrogens could carry more weight (Wolters and Hahn, 2004; Petrakis et al., 1996; 
McMichael-Phillips et al., 1998; de Lemos, 2001).  
 
The increase in endometrium hyperplasias in women during and after menopause can be 
considered a negative effect of isoflavones whereby the risk of neoplasias increases (Unfer 
et al., 2004; Johnson et al., 2001).  
 
Here it should be borne in mind that in contrast to a specifically timed, clinically controlled 
study, possible risk groups could ingest these substances from food supplements for years 
without any medical supervision. There are no long-term studies which confirm the safety of 
isoflavone products. Therefore, it is not possible to make any statements about the dose 
which could still be deemed safe. Hence BfR is of the opinion that women with an estrogen 
receptor positive mammary carcinoma or endometrium carcinoma or who are at greater risk 
of these diseases should not use these products. Since women during or after menopause 
are not aware of this risk, BfR generally advises against the consumption of food supple-
ments based on isoflavones.   
 
Although it is difficult to assess the potential of goitrogenic effects of isoflavones on the thy-
roid gland, women with increasing age run a higher risk of developing sub-clinical thyroid 
underfunction. Given the present data situation, it cannot therefore be ruled out that this risk 
is elevated by taking isoflavone products (SKLM, 2006). 
 
3.1.6.2  Observed adverse effects 
 
The observed intolerance reactions would seem to indicate that the proportion of soy protein 
in the food supplements is probably responsible for the allergic reaction. The prevalence of 
food-related allergies in the general population is estimated to be around 1-3% of adults and 
4-6% of children (EFSA, 2004). A clinical detection of an existing hypersensitivity reaction to 
soy was not verified in the reported cases. Overall an assessment of these adverse effects is 
not possible on the basis of the available indications. Furthermore, no causal relationship can 
be established particularly as in most cases no medical findings were available. 
 
3.2 Discussion 
It is important to distinguish between the intake of phyto-estrogens from food and in isolated 
form. Phyto-estrogens seem to be able to influence a number of functions in the human 
body. As they bind to the same receptors as endogenous estrogens, albeit with a far lower 
hormonal impact, they could theoretically have a favourable impact on carcinogenesis, par-
ticularly on breast and prostate cancer and, under certain circumstances, on cardiovascular 
diseases and osteoporosis. The current level of knowledge about the effects of phyto-
estrogens and a number of other bioactive plant substances is not, however, sufficient in 
order to be able to give intake recommendations for specific individual substances. In popu-
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lation studies the consumption of soy products was linked to various health advantages. 
Hence a diet which is rich in soy products, cereals, vegetables and fruit is recommended. 
German, Austrian and Swiss nutrition societies advise against taking food supplements con-
taining concentrated bioactive plant substances as it is not known which bioactive plant sub-
stances or which amounts of them have a preventive effect (D-A-CH, 2000; Grossklaus, 
2000).  
 
Some patients switch to phyto-estrogens because of the adverse effects of hormone re-
placement therapy (HRT) during menopause. The target group of isoflavone products is 
mainly women close to / after menopause who are looking for an alternative to hormone re-
placement therapy. Vasomotor symptoms like hot flushes and sweating in particular are to be 
relieved. Information that Japanese women suffered less frequently from menopausal com-
plaints than Europeans led to the hypothesis that the high soy consumption in Japan and the 
related lifelong higher intake of soy isoflavones could be contributory factors. It is not yet 
clear whether there is a causal relationship or whether soy consumption is simply a marker 
for a healthier lifestyle. 
 
At the present time isolated isoflavones are ingredients in food supplements and foods for 
special medical purposes which are targeted above all at women close to/after menopause. 
Most of the studies that examined whether the additional intake of isolated isoflavones could 
relieve menopausal symptoms did, however, come to the conclusion that given the strong 
placebo effect and a time-dependent decrease in menopausal complaints, significant and 
clinically relevant effects were not detectable in most cases. Placebo-controlled studies fre-
quently show that already under placebo the vasomotor menopausal symptoms could be 
improved by 30-50%. A comparison of verum with the placebo or control did not reveal any 
significant superiority of isoflavone administration in the vast majority of cases. Overall the 
positive effect of isolated isoflavones on menopausal complaints has not been sufficiently 
scientifically substantiated up to now (Davis, 2001; AMB, 2001).  
 
On the other hand in studies with isoflavones from soybean protein or fermented soy protein 
products, an impact on the endocrine function in humans could already be demonstrated at 
doses of 50 mg/day and higher which are in the upper range of Asian countries with a high 
consumption of soybeans and the customary soy foods found there: in menstruating women 
estrogen-like inhibition effects on the hypothalamus/pituitary gland with prolongation of the 
follicle phase of the cycle (Cassidy et al., 1995; Cassidy et al., 1994); prolongation of men-
struation (Watanabe et al., 2000) and in women during and after menopause signs of estro-
genic effects on the vaginal mucosa (Wilcox et al., 1990).  
 
Studies showed that the bioavailability of the ingredients in various food supplements con-
taining isolated isoflavones varies considerably (Setchell et al., 2001). Furthermore, daidzein 
in isolated form seems to have higher bioavailability than in the natural matrix as soy flour 
(Anupongsanugool et al., 2005). The exact composition (total isoflavone content, isoflavone 
spectrum, food matrix) of food supplements is not generally known or standardised. SKLM 
(2005; 2006) is, therefore, of the opinion that a safety assessment would have to be under-
taken for each product. In Canada the addition of bioactive substances to foods is classified 
as novel foods and must undergo authorisation and examination in each individual case 
(Lee, 2006). According to Whereas no. 8 of the Food Supplements Ordinance, specific provi-
sions about nutrients other than vitamins and minerals or about other substances with a nu-
tritional or physiological effect, which are used as ingredients in food supplements, should be 
specified at a later point in time when sufficient, unbiased data are available on these sub-
stances. As national provisions may be used until the issuing of special Community provi-
sions of this nature, BfR recommends another management option which would involve 
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equating these substances pursuant to § 2 para 3 No. 1 sentence 2 LFGB (Food and Feed 
Code) with food additives.  
 
Up to now no sufficient safety data for humans, particularly on long-term administration, have 
been available. Relevant toxicological effects cannot be ruled out and indications of adverse 
effects can be derived from existing studies. Against this backdrop and because of the insuf-
ficiently proven efficacy, BfR is of the opinion that non-critical product advertising is problem-
atic because of the possibility of misleading consumers in terms of food law. Depending on 
origin, raw material and production the commercial preparations containing isolated isofla-
vones vary considerably as do the total content, the relations of isoflavones to each other, 
the forms of the different isoflavones used and the recommended daily doses. This means 
that the comparability of the various preparations but also the comparability of studies with 
not exactly defined isoflavone products is not possible or only possible to a very limited de-
gree (Erdman et al., 2004).  
 
The negative effects of isoflavones on the uterus mucosa and the risk of endometrium carci-
nomas must be viewed very critically. Given the safety concerns prompted by the study by 
Unfer et al. (2004), isolated soy isoflavones in the tested dose (150 mg/day) cannot be rec-
ommended particularly as there is no clear proof of advantages and the side effects linked to 
long-term administration cannot be calculated (a-t, 2004; a-t, 2001; a-t, 2002; a-t, 2003). Ac-
cording to Wolters and Hahn "an oral dose of 50 mg isoflavones daily seems to be safe for 
the majority of the population" and it could be assumed on the basis of the study data that 
the short-term administration of soy products was not linked to major adverse effects. None-
theless, the authors do recommend that women with estrogen receptor positive mammary 
carcinoma, endometrium carcinoma or an elevated risk of these diseases, should not take 
isolated isoflavones, for instance as food supplements (Wolters and Hahn, 2004). 
 
The probability of adverse health effects, i.e. that the long-term administration of isoflavone-
containing food supplements or supplemented foods for medical purposes could increase the 
risk of breast cancer, is deemed to be high particularly in the risk group of menopausal 
women. More particularly women taking tamoxifen as medication to prevent breast cancer or 
undergoing adjuvant or palliative treatment for breast cancer should be informed of this ele-
vated risk (De Lemos, 2001; This et al., 2001). 
 
In the conclusions of their publication Kroll et al. give a critical assessment of the uncertain 
data situation about the effects of isolated isoflavones on humans as follows, "As far as the 
physiological effects of isoflavones are concerned, a flood of publications emphasise above 
all their positive effects. These positive effects are derived on the one hand from the fact that 
in a number of Asian countries soy products have been a traditional and staple part of the 
human diet for centuries and that in these countries the risk of specific diseases (hormone-
dependent types of cancer… osteoporosis) and menopausal symptoms is lower than in 
western industrial nations. On the other hand, the positive effects of isoflavones described 
were established first and foremost for isolated compounds, mostly by drawing on model 
systems, and in every case from the interpretation of nutritional-epidemiological studies. In 
many cases the results obtained are seen as evaluation criteria for corresponding food sup-
plements. The negative effects which are also described that may occur in conjunction with 
comparatively high, long-term ingestion of isoflavones from food supplements, are not taken 
into account at all in this context. As is the case for most bioactive plant substances, the op-
timum physiological effects are not known for isoflavones either" (Kroll et al., 2004). 
 
In its assessment from 2003 the British COT (Committee on Toxicity of Chemicals in Food, 
Consumer Products and the Environment) identified people with thyroid underfunction and 
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women with oestrogen-dependent diseases of the mammary gland as possible risk groups 
for phyto-estrogen supplementation. COT comes to the conclusion that overall the available 
data are not sufficient for more precise recommendations. In conjunction with the effects of 
soy-based isolated isoflavones on menopausal symptoms, "Studies examining the effect of 
soy-based products or isoflavones to relieve menopausal symptoms are inconclusive. Some 
studies have suggested that soy may be beneficial, especially if basal intake is low, or the 
vasomotor symptoms severe, but the data are equivocal, as positive results are often not 
statistically significant and strong placebo responses are observed" (COT, 2003). 
 
In the comprehensive meta-analysis by Trock et al., (2006) regarding a possible inverse as-
sociation between the ingestion of soy foods and the risk of breast cancer, the authors con-
clude that given the existing uncertainties and animal experiment findings about possible 
adverse health effects of soy ingredients, it is too early to hand down recommendations for 
highly dosed isoflavone products for breast cancer prevention (Trock et al., 2006). 
 
Given the difficulty of transferring animal data to humans and the problem that only very few 
clinical studies are available and their statements are inconsistent, a definitive assessment of 
the effect of isoflavones on the female breast, particularly regarding the breast cancer risk of 
women at higher risk or the survival time of breast cancer patients, is not possible at present 
(Messina et al., 2006, Rice and Whitehead, 2006). Data available up to now from prospective 
studies on the elevated intake of isoflavone-containing foods do not point to any lowering of 
the breast cancer rate or possible favourable trends are only interpreted with reservations 
and constraints and are deemed to be provisional (Trock et al., 2006). The available data do, 
however, permit the conclusion that isoflavones – particular at high doses – can lead to es-
trogenic stimulus of mammary gland tissue in women and, by extension, that the growth 
stimulus of pre-malignant or tumour cells through the ingestion of elevated amounts of isofla-
vone products cannot be ruled out (SKLM, 2006). In its assessment SKLM comes to the 
conclusion that the safety of isoflavone products on a soy or red clover basis as food sup-
plements and foods for special medical purposes cannot be established from the traditional 
administration of soy foods (SKLM, 2006). In its opinion "the potential of isoflavones in prod-
ucts of this kind to trigger adverse health effects and the dose-dependency of these effects 
have not yet been sufficiently examined". SKLM is of the opinion that what is particularly 
problematic is that "postmenopausal women (women during and after menopause), who are 
the main target group for these products, are also a special risk group for adverse effects”.  
Given the current data situation it cannot be ruled out that this group which is already at risk 
will be at even greater risk of an increased development of pre-carcinogenic changes to the 
breast or the formation of a sub-clinical thyroid underfunction (SKLM, 2006). 
 
4 Management framework/measures 
From the nutritional-medical point of view and according to the latest knowledge available, 
the claimed positive effects of isoflavones on menopausal symptoms have not been suffi-
ciently substantiated. Bearing in mind the special sensitivity of the consumer group of women 
during and after menopause, the safety of products containing isolated isoflavones on a soy 
or red clover basis has not been sufficiently proven. In this context any adverse carcinogenic, 
goitrogenic effects or other adverse effects on the hormone balance are of particular impor-
tance. BfR concludes that there are health risks with low probability from food supplements 
of this kind and from foods for special medical purposes for women during and after meno-
pause. Therefore, BfR recommends there is a need for action, for instance to raise aware-
ness amongst women with breast cancer or a predisposition for this type of cancer. 
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